The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized phase II trial of fulvestrant with or without ribociclib after progression on aromatase inhibition plus cyclin-dependent kinase 4/6 inhibition in patients with unresectable or metastatic hormone receptor positive, HER2 negative breast cancer.
 
Kevin Kalinsky
Employment - Novartis (I)
Stock and Other Ownership Interests - Novartis (I)
Honoraria - Amgen; AstraZeneca; Immunomedics; pfizer
Consulting or Advisory Role - bioTheranostics; Lilly
 
Prabhjot Singh Mundi
No Relationships to Disclose
 
Codruta Chiuzan
No Relationships to Disclose
 
Melissa Kate Accordino
No Relationships to Disclose
 
Meghna S. Trivedi
No Relationships to Disclose
 
Joseph A. Sparano
Stock and Other Ownership Interests - Metastat
Consulting or Advisory Role - AstraZeneca; Celgene; Celldex; Genentech/Roche; Juno Therapeutics; Lilly; Merrimack; Novartis; Pfizer; Prescient Therapeutics
Research Funding - Deciphera (Inst); Genentech/Roche (Inst); Merck (Inst); Merrimack (Inst); Novartis (Inst); Novartis (Inst); Prescient Therapeutics (Inst)
 
Sun Young Oh
No Relationships to Disclose
 
Amy Tiersten
No Relationships to Disclose
 
Ruth O'Regan
Honoraria - Genomic Health; Roche
Consulting or Advisory Role - Eisai; Genentech; Lilly; Pfizer; Puma Biotechnology
Travel, Accommodations, Expenses - BIND Biosciences; Celgene; Genentech; Genomic Health; Lilly; Novartis; Roche
 
Francisco J. Esteva
Consulting or Advisory Role - Celgene; Celltrion; Genentech/Roche; NanoString Technologies; Novartis; Spectrum Pharmaceuticals
Research Funding - Kadmon (Inst); Merrimack (Inst); Novartis (Inst); Synta (Inst)
Patents, Royalties, Other Intellectual Property - Myriad Genetics (royalties)
Travel, Accommodations, Expenses - Novartis
 
Sarika Jain
No Relationships to Disclose
 
Ingrid A. Mayer
Consulting or Advisory Role - AstraZeneca; Novartis
Research Funding - Novartis; Pfizer
 
Andres Forero
No Relationships to Disclose
 
Lea N. Baer
No Relationships to Disclose
 
Katherine D. Crew
No Relationships to Disclose
 
Dawn L. Hershman
No Relationships to Disclose
 
Christos Vaklavas
No Relationships to Disclose